BLB-301

BLB-301 is a preclinical-stage therapeutic candidate developed by BayLink Biosciences for the treatment of solid tumors. It utilizes a dual mechanism of action, functioning as both a protein degrader and a topoisomerase 1 (TOP1) inhibitor. This bifunctional approach is designed to leverage the synergistic effects of targeted protein degradation (TPD) and DNA damage induction to overcome resistance mechanisms and enhance efficacy in oncology indications. While the specific protein target for the degradation component remains undisclosed by the sponsor, the compound represents a novel class of agents combining these two potent anti-tumor modalities within a single molecule.